Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)

Francesco Vizzutti, Umberto Arena, Valerio Nobili, Roberto Tarquini, Marco Trappoliere, Giacomo Laffi, Fabio Marra, Massimo Pinzani

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries, and its prevalence is increasing worldwide. It currently affects approximately 30% of adults and 10% of children and adolescents. The resulting increase in the number of patients with NAFLD is expected to translate into increased numbers of patients with liver cirrhosis, and hepatocellular carcinoma. In this context, it is particularly important to identify patients at risk for progressive chronic liver disease. Currently, liver biopsy is the gold standard to diagnose non-alcoholic steatohepatitis (NASH) and to establish the presence and stage of fibrosis. Due to the remarkable increase in the prevalence of NAFLD and the concomitant efforts in developing novel therapies for patients with NASH, non-invasive, simple, reproducible, and reliable noninvasive methodologies are needed. This paper provides a concise overview of the role of non-invasive diagnostic tools for the determination of presence and extent of fibrosis in NAFLD patients, with particular emphasis on the methods currently available in clinical practice.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalAnnals of Hepatology
Volume8
Issue number2
Publication statusPublished - Apr 2009

Fingerprint

Fibrosis
Fatty Liver
Liver Diseases
Chronic Disease
Liver Cirrhosis
Hepatocellular Carcinoma
Non-alcoholic Fatty Liver Disease
Biopsy
Liver
Therapeutics

Keywords

  • Fibrosis
  • NAFLD
  • NASH
  • Non-invasive

ASJC Scopus subject areas

  • Hepatology

Cite this

Vizzutti, F., Arena, U., Nobili, V., Tarquini, R., Trappoliere, M., Laffi, G., ... Pinzani, M. (2009). Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology, 8(2), 89-94.

Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). / Vizzutti, Francesco; Arena, Umberto; Nobili, Valerio; Tarquini, Roberto; Trappoliere, Marco; Laffi, Giacomo; Marra, Fabio; Pinzani, Massimo.

In: Annals of Hepatology, Vol. 8, No. 2, 04.2009, p. 89-94.

Research output: Contribution to journalArticle

Vizzutti, F, Arena, U, Nobili, V, Tarquini, R, Trappoliere, M, Laffi, G, Marra, F & Pinzani, M 2009, 'Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)', Annals of Hepatology, vol. 8, no. 2, pp. 89-94.
Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, Laffi G et al. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology. 2009 Apr;8(2):89-94.
Vizzutti, Francesco ; Arena, Umberto ; Nobili, Valerio ; Tarquini, Roberto ; Trappoliere, Marco ; Laffi, Giacomo ; Marra, Fabio ; Pinzani, Massimo. / Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). In: Annals of Hepatology. 2009 ; Vol. 8, No. 2. pp. 89-94.
@article{98bf4140326d45feac826fdb6b839b74,
title = "Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries, and its prevalence is increasing worldwide. It currently affects approximately 30{\%} of adults and 10{\%} of children and adolescents. The resulting increase in the number of patients with NAFLD is expected to translate into increased numbers of patients with liver cirrhosis, and hepatocellular carcinoma. In this context, it is particularly important to identify patients at risk for progressive chronic liver disease. Currently, liver biopsy is the gold standard to diagnose non-alcoholic steatohepatitis (NASH) and to establish the presence and stage of fibrosis. Due to the remarkable increase in the prevalence of NAFLD and the concomitant efforts in developing novel therapies for patients with NASH, non-invasive, simple, reproducible, and reliable noninvasive methodologies are needed. This paper provides a concise overview of the role of non-invasive diagnostic tools for the determination of presence and extent of fibrosis in NAFLD patients, with particular emphasis on the methods currently available in clinical practice.",
keywords = "Fibrosis, NAFLD, NASH, Non-invasive",
author = "Francesco Vizzutti and Umberto Arena and Valerio Nobili and Roberto Tarquini and Marco Trappoliere and Giacomo Laffi and Fabio Marra and Massimo Pinzani",
year = "2009",
month = "4",
language = "English",
volume = "8",
pages = "89--94",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "2",

}

TY - JOUR

T1 - Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD)

AU - Vizzutti, Francesco

AU - Arena, Umberto

AU - Nobili, Valerio

AU - Tarquini, Roberto

AU - Trappoliere, Marco

AU - Laffi, Giacomo

AU - Marra, Fabio

AU - Pinzani, Massimo

PY - 2009/4

Y1 - 2009/4

N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries, and its prevalence is increasing worldwide. It currently affects approximately 30% of adults and 10% of children and adolescents. The resulting increase in the number of patients with NAFLD is expected to translate into increased numbers of patients with liver cirrhosis, and hepatocellular carcinoma. In this context, it is particularly important to identify patients at risk for progressive chronic liver disease. Currently, liver biopsy is the gold standard to diagnose non-alcoholic steatohepatitis (NASH) and to establish the presence and stage of fibrosis. Due to the remarkable increase in the prevalence of NAFLD and the concomitant efforts in developing novel therapies for patients with NASH, non-invasive, simple, reproducible, and reliable noninvasive methodologies are needed. This paper provides a concise overview of the role of non-invasive diagnostic tools for the determination of presence and extent of fibrosis in NAFLD patients, with particular emphasis on the methods currently available in clinical practice.

AB - Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries, and its prevalence is increasing worldwide. It currently affects approximately 30% of adults and 10% of children and adolescents. The resulting increase in the number of patients with NAFLD is expected to translate into increased numbers of patients with liver cirrhosis, and hepatocellular carcinoma. In this context, it is particularly important to identify patients at risk for progressive chronic liver disease. Currently, liver biopsy is the gold standard to diagnose non-alcoholic steatohepatitis (NASH) and to establish the presence and stage of fibrosis. Due to the remarkable increase in the prevalence of NAFLD and the concomitant efforts in developing novel therapies for patients with NASH, non-invasive, simple, reproducible, and reliable noninvasive methodologies are needed. This paper provides a concise overview of the role of non-invasive diagnostic tools for the determination of presence and extent of fibrosis in NAFLD patients, with particular emphasis on the methods currently available in clinical practice.

KW - Fibrosis

KW - NAFLD

KW - NASH

KW - Non-invasive

UR - http://www.scopus.com/inward/record.url?scp=67650558987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650558987&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 89

EP - 94

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 2

ER -